Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) and Cronos Group (NASDAQ:CRON – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.
Institutional and Insider Ownership
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 6.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Aurinia Pharmaceuticals has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 4 | 2 | 0 | 2.33 |
| Cronos Group | 1 | 2 | 2 | 0 | 2.20 |
Aurinia Pharmaceuticals presently has a consensus target price of $17.25, indicating a potential upside of 7.95%. Cronos Group has a consensus target price of $2.30, indicating a potential downside of 14.18%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Aurinia Pharmaceuticals is more favorable than Cronos Group.
Profitability
This table compares Aurinia Pharmaceuticals and Cronos Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | 101.46% | 27.47% | 19.61% |
| Cronos Group | -6.44% | -1.12% | -1.07% |
Valuation and Earnings
This table compares Aurinia Pharmaceuticals and Cronos Group”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $283.05 million | 7.34 | $287.20 million | $2.08 | 7.68 |
| Cronos Group | $146.59 million | 6.88 | -$9.45 million | ($0.01) | -268.00 |
Aurinia Pharmaceuticals has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Aurinia Pharmaceuticals beats Cronos Group on 13 of the 13 factors compared between the two stocks.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
About Cronos Group
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
